TwinStrand Biosciences Announces Executive Leadership Changes to Accelerate Adoption of Duplex Sequencing for Minimal Residual Disease (MRD) Testing for Hematological Malignancies and Cell Therapy Monitoring

Samba Scientific Case Studies | Life Science and Biotech Marketing Agency | Twinstrand
  • Duplex Sequencing can deliver 10,000x greater accuracy than standard NGS allowing for exquisitely sensitive mutation and genetic allele detection to inform critical medical decisions and drug development pipelines
  • Experienced Molecular Diagnostics executive, Ron Andrews, appointed as President and CEO and Board Member
  • David Canner, PhD, from Soleus Capital and Jason Myers, PhD, co-founder of ArcherDx(Invitae) have both joined the Board of Directors

SEATTLE, Aug. 29, 2023 /PRNewswire/ — TwinStrand Biosciences®, the pioneer in Duplex Sequencing technology, which delivers accurate insights to researchers in applications ranging from residual cancer detection to genetic toxicology announced the appointment of Ron Andrews, as Chief Executive Officer and Board Member. TwinStrand® is also pleased to announce that David Canner, Partner at Soleus Capital, and Jason Myers, Independent Director, will join the TwinStrand Board of Directors. TwinStrand currently provides Duplex Sequencing assays for research use for minimal residual disease detection and genomic safety via the company’s off-the-shelf kit solutions utilized on installed NGS platforms.

Read the full article on

Share this page on social

Ready to get started? See what Samba can do for you.